摘要
目的 :研究葡甘聚糖对大鼠口服荧光素钠药动学的影响。方法 :利用荧光素钠作为示踪药物 ,HPLC反相柱色谱分离原药 ,荧光高效液相法定量分析血清荧光素钠含量。结果 :大鼠灌胃荧光素钠溶液T12 α为 (5 .0± 0 .9)min ,T12 β为 (43± 9)min ,Tmax为 (7.5± 0 )min ,Cmax为 (192± 7)mg·L- 1,AUC为 (83± 17) μg·h- 1·L- 1。以 0 .4 %或 0 .8%的葡甘聚糖为制剂时T12 α分别为 (2 0± 6 )min和 (38± 13)min ,T12 β为 (6± 3)h和 (2 5± 12 )h ,Tmax为(19± 9)min和 (40± 16 )min ,Cmax为 (92 .3± 2 .0 )mg·L- 1和 (5 2± 3)mg·L- 1,AUC为 (6 14± 10 5 ) μg·h- 1·L- 1和 (30 1± 2 2 ) μg·h- 1·L- 1。结论 :葡甘聚糖能明显改变口服药物的药动学参数 ,如降低血药峰值浓度 ,提高AUC。
AIM: To study the effect of glucomannan on the pharmacological kinetic character of fluorescein sodium. METHOD: The contents of fluorescein sodium in serum were analysed with fluorescent HPLC after separation with fluorescein sodium as trace agent. RESULTS:After ig fluorescein sodium solution, the blood concentration time curve was shown to fit 2 compartment with T 12α =(5.0±0.9) min and T 12β =(43±9) min, T max =(7.5±0) min, C max =(192±7) mg/L -1 and AUC=(83±17) μg·h·L -1 , when ig fluorescein sodium of polysaccharide preparations with 0.4 % or 0.8 % glucomannan, the T 12α , T 12β , T max , C max and AUC were (20±6) min or (38±13) min, (6±3) h or (25±12) h, (19±9) min or (40±16) min, (92.3±2.0) mg·L -1 or (52±3) mg·L -1 and (614±105) μg·h -1 ·L -1 or (301±22) μg·h -1 ·L -1 . CONCLUSION:Glucomannan can obviously improve the parameters of pharmacokinetics, such as extending the maintenance time of blood concentration, cutting down the peak concentration and enlarging AUC remarkably.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2002年第1期23-25,共3页
Chinese Journal of New Drugs and Clinical Remedies
基金
国家新药研究基金资助项目 (96 90 1 0 5 2 40 )
关键词
葡甘聚糖
多糖类
荧光素钠
药动学
glucomannan
polysaccharides
fluorescein sodium
pharmacokinetics
